Precigen Quarterly Cash Flow Statement
NASDAQ: PGENHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.81+0.21 (+2.76%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Precigen free cash flow
In the quarter ended Jun 30, 2026, Precigen generated -$17.8 million of operating cash flow and spent $392,000 on capital expenditures. That left free cash flow of -$18.2 million, a free-cash-flow margin of -33.1% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Precigen cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 20.07M | -7.93M | -23.50M | -146.34M | -26.64M | -54.15M | -19.73M | -23.98M | -58.79M | -23.74M | -33.06M | -19.80M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | -122.65% |
| Depreciation & Amortization | 1.10M | 1.10M | 1.14M | 803.00K | 630.00K | 629.00K | 661.00K | 674.00K | 1.60M | 1.59M | 1.61M | 1.65M |
| Stock-Based Compensation | 3.58M | 3.01M | 2.16M | 4.39M | 1.64M | 2.68M | 2.87M | 2.06M | 1.96M | 2.58M | 2.26M | 2.31M |
| Change in Working Capital | -48.46M | -36.86M | -3.29M | -3.48M | 913.00K | -136.00K | -1.10M | -548.00K | 838.00K | 2.65M | -530.00K | 637.00K |
| Operating Cash Flow | -17.81M | -43.83M | -23.46M | -29.07M | -18.98M | -16.32M | -8.24M | -22.73M | -23.11M | -14.09M | -15.77M | -17.01M |
| Capital Expenditures | -392.00K | -258.00K | -18.00K | -389.00K | -966.00K | -622.00K | -1.03M | -882.00K | -2.32M | -4.35M | -1.04M | -236.00K |
| Investing Cash Flow | 26.69M | 20.97M | 39.87M | -63.39M | 28.44M | -6.46M | -65.37M | 5.65M | 14.96M | 24.05M | 13.29M | 10.53M |
| Debt Issued | — | — | -654.00K | — | — | — | 0 | — | — | — | — | — |
| Debt Repaid | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | -33.00K | 109.00K | -514.00K | 93.01M | -1.77M | -679.00K | 78.40M | 32.13M | 52.00K | 0 | 0 | 0 |
| Net Change in Cash | 8.85M | -22.75M | 15.91M | 562.00K | 7.70M | -23.46M | 4.79M | 15.12M | -8.13M | 9.89M | -2.49M | -6.62M |
| Free Cash Flow | -18.20M | -44.09M | -23.48M | -29.46M | -19.94M | -16.95M | -9.27M | -23.61M | -25.43M | -18.44M | -16.81M | -17.24M |
This table shows 12 quarterly periods of Precigen's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PGEN's reporting calendar. What is a cash flow statement?